Accelerating Nuclear Medicine Ⅰ —— Why Cyclotrons Matter in Modern Healthcare

2026-05-12

🔬 Nuclear medicine helps clinicians see disease at a molecular level.

Unlike CT or MRI, which mainly show structural changes, nuclear medicine can reveal biological processes inside the body, such as metabolism, blood flow and receptor expression.

⚙️ Behind many of these applications is a key technology: the cyclotron.

A cyclotron is a particle accelerator. It uses magnetic and electric fields to accelerate charged particles, which are then used to produce medical radionuclides. These radionuclides can be combined with specific molecules to form radiopharmaceuticals for PET imaging and other nuclear medicine applications.

💉 One well-known example is F-18 FDG, widely used in PET imaging for oncology, neurology and cardiology. Other radionuclides, such as C-11, N-13 and O-15, also support specific clinical and research applications.

⏱️ Because many medical radionuclides have short half-lives, stable local or regional production is essential. This is why cyclotrons are considered key infrastructure for PET centers, radiopharmaceutical production facilities and nuclear medicine departments.

🏗️ A cyclotron is not just a standalone machine. A complete production platform may also include target systems, synthesis modules, dispensing systems, quality control, radiation monitoring, shielding design, installation, training and long-term service support.

📌 Therefore, choosing a cyclotron depends not only on the equipment model, but also on the intended isotopes, production capacity, clinical applications, site conditions and regulatory requirements.

At LBT, we believe a well-designed cyclotron-based platform should support both routine PET imaging and future radiopharmaceutical development.

Actual configuration should be determined based on clinical goals, isotope portfolio, production capacity, site conditions, regulatory requirements and project planning.

➡️ In the next article, we will discuss how radiopharmaceutical production is moving from FDG-centered workflows toward multi-isotope platforms.